Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.

Date publication

septembre 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr MASSARD Vincent

Tous les auteurs :
Varnier R, Pérol D, Jacot W, Mailliez A, Diéras V, Dalenc F, Gonçalves A, Levy C, Arnedos M, Frenel JS, Bailleux C, Massard V, Brain E, Sauterey B, Savoye AM, Bosquet L, Thery JC, Petit T, Bachelot T, Grinda T, Ray-Coquard I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40967066

Résumé

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved the prognosis of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), but their impact on the efficacy of second-line treatments remains poorly described.

Mots clés

CDK4/6 inhibitor, breast cancer, cross-resistance, second-line therapy, treatment patterns

Référence

ESMO Open. 2025 09 17;10(10):105803